Dr. Reddy’s Laboratories Selects LifeSphere® Signal and Risk Management

Jan 21, 2021

The leading multination pharmaceutical company plans to use ArisGlobal’s platform to deliver the next generation of integrated signal detection and risk management globally.

Miami, FL January 21, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), an integrated global pharmaceutical company committed to providing affordable and innovative medicines for healthier lives, has selected ArisGlobal’s LifeSphere® Signal and Risk Management as the next-generation signal detection and risk management system for its global pharmacovigilance team.


“LifeSphere Signal and Risk Management delivers unparalleled efficiency gains for our PV team.  We can simultaneously connect to both internal and external sources of safety-related data for analysis. Incorporating LifeSphere Signal and Risk Management has allowed us to identify, assess, and communicate safety risks and signals automatically and leverage data to better understand the benefit-risk profile of our products” said Kay Saywell, Global Head of Pharmacovigilance, Dr. Reddy’s Laboratories. “We’re excited to leverage this technology and continue growing our relationship with ArisGlobal.”


LifeSphere Signal and Risk Management is an integrated platform featuring safety intelligence and risk mitigation solutions. Built-in automation, enhanced with artificial intelligence, improves efficiency through automated signal management, prioritizes safety observations, and classifies signals from adverse events and bio-medical literature to reduce false positives.


“We are very pleased that Dr. Reddy’s has integrated LifeSphere Signal and Risk Management into their safety environment,” said Sankesh Abbhi, ArisGlobal’s President and CEO. “Our multi-tenant safety cloud is first to market with production-ready automation. We are grateful for their partnership and look forward to building upon an already great relationship.”


In addition to LifeSphere Signal and Risk Management, Dr. Reddy’s leverages ArisGlobal’s LifeSphere MultiVigilance as its drug safety system, and they have deployed LifeSphere Medical Information and LifeSphere Product Complaints to handle their medical affairs needs.


Dr. Reddy’s joins more than 300 life science companies benefiting from ArisGlobal’s state-of-the-art cloud safety technology. To learn more, visit: https://www.arisglobal.com/products/lifesphere-signal-and-risk-management-agbalance/


About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses  – Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services. Major markets include the USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com



About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn: linkedin.com/company/aris-global
Follow @Aris_Global on Twitter: twitter.com/aris_global


Erika Thomas
+305-726-6601 | ethomas@arisglobal.com